Alebund Pharmaceuticals Sets 26 August 2026 Board Meeting to Approve 1H26 Interim Results

Bulletin Express

08/13

Alebund Pharmaceuticals (Jiangsu) Limited announced that its board of directors will convene on Wednesday, 26 August 2026. The meeting’s agenda includes reviewing and approving the Group’s interim financial results for the six months ended 30 June 2026 and confirming their subsequent publication.

The notice, dated 13 August 2026, was issued under the authority of Chairman, Executive Director and Chief Executive Officer Dr. Gavin Guoyao Xia.

The current board comprises: • Executive Directors – Dr. Gavin Guoyao Xia, Jin Tian, M.D., Ms. Wang Yun and Dr. Zhang Huading • Non-executive Director – Dr. Lu An • Independent Non-executive Directors – Dr. Xu Runhong, Dr. Zhui Chen and Mr. Leung Chi Wai

No additional financial figures were disclosed in the announcement; detailed performance metrics will be available upon the release of the interim results following board approval.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1162000898"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162000898\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162000898?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162000898","market":"us","top_or_hot":-1,"title":"Alebund Pharmaceuticals Sets 26 August 2026 Board Meeting to Approve 1H26 Interim Results","media":"Bulletin Express","content":"<p>Alebund Pharmaceuticals (Jiangsu) Limited announced that its board of directors will convene on Wednesday, 26 August 2026. The meeting’s agenda includes reviewing and approving the Group’s interim financial results for the six months ended 30 June 2026 and confirming their subsequent publication.</p>\n<p>The notice, dated 13 August 2026, was issued under the authority of Chairman, Executive Director and Chief Executive Officer Dr. Gavin Guoyao Xia.</p>\n<p>The current board comprises:  \n• Executive Directors – Dr. Gavin Guoyao Xia, Jin Tian, M.D., Ms. Wang Yun and Dr. Zhang Huading  \n• Non-executive Director – Dr. Lu An  \n• Independent Non-executive Directors – Dr. Xu Runhong, Dr. Zhui Chen and Mr. Leung Chi Wai</p>\n<p>No additional financial figures were disclosed in the announcement; detailed performance metrics will be available upon the release of the interim results following board approval.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alebund Pharmaceuticals Sets 26 August 2026 Board Meeting to Approve 1H26 Interim Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlebund Pharmaceuticals Sets 26 August 2026 Board Meeting to Approve 1H26 Interim Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-13 19:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Alebund Pharmaceuticals (Jiangsu) Limited announced that its board of directors will convene on Wednesday, 26 August 2026. The meeting’s agenda includes reviewing and approving the Group’s interim financial results for the six months ended 30 June 2026 and confirming their subsequent publication.</p>\n<p>The notice, dated 13 August 2026, was issued under the authority of Chairman, Executive Director and Chief Executive Officer Dr. Gavin Guoyao Xia.</p>\n<p>The current board comprises:  \n• Executive Directors – Dr. Gavin Guoyao Xia, Jin Tian, M.D., Ms. Wang Yun and Dr. Zhang Huading  \n• Non-executive Director – Dr. Lu An  \n• Independent Non-executive Directors – Dr. Xu Runhong, Dr. Zhui Chen and Mr. Leung Chi Wai</p>\n<p>No additional financial figures were disclosed in the announcement; detailed performance metrics will be available upon the release of the interim results following board approval.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09637","symbol_name":"礼邦医药-B","start_time":0,"source_url":"","article_id":"1162000898","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162000898","pubTimestamp":1786621402,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Alebund Pharmaceuticals (Jiangsu) Limited announced that its board of directors will convene on Wednesday, 26 August 2026. The meeting’s agenda includes reviewing and approving the Group’s interim...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09637":"礼邦医药-B"},"translate_title":"Alebund Pharmaceuticals 定于 2026 年 8 月 26 日召开董事会会议批准 26 年上半年中期业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09637":1},"content_text":"Alebund Pharmaceuticals (Jiangsu) Limited announced that its board of directors will convene on Wednesday, 26 August 2026. The meeting’s agenda includes reviewing and approving the Group’s interim financial results for the six months ended 30 June 2026 and confirming their subsequent publication.\nThe notice, dated 13 August 2026, was issued under the authority of Chairman, Executive Director and Chief Executive Officer Dr. Gavin Guoyao Xia.\nThe current board comprises:  \n• Executive Directors – Dr. Gavin Guoyao Xia, Jin Tian, M.D., Ms. Wang Yun and Dr. Zhang Huading  \n• Non-executive Director – Dr. Lu An  \n• Independent Non-executive Directors – Dr. Xu Runhong, Dr. Zhui Chen and Mr. Leung Chi Wai\nNo additional financial figures were disclosed in the announcement; detailed performance metrics will be available upon the release of the interim results following board approval.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}